ARTICLE | Clinical News
Myl-1401O regulatory update
November 10, 2016 11:26 PM UTC
Mylan and Biocon said Mylan submitted a BLA to FDA for Myl-1401O, a biosimilar of Herceptin trastuzumab, to treat HER2-positive breast and gastric cancers. In August, EMA accepted for review an MAA fo...
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)